OBJECTIVE:
To assess fetal and maternal outcomes pre and post a diagnosis of a systemic autoimmune rheumatic disease (SARD). STUDY DESIGN: We conducted a retrospective cohort study from a perinatal registry including all pregnancies in British Columbia from January 1 st , 2002 to December 31 st , 2012. SARDs was defined as one ICD-9/10 hospital code, or ¼/> 2 ICD-9/ICD-10 MSP codes at least 2 months apart in a 2 -year window. All connective tissue diseases were included: systemic lupus erythematosus, scleroderma/systemic sclerosis, Sjogren's syndrome, dermatomyositis, polymyositis. SARDs exposure was based on diagnosis before or after date of conception. The groups were defined as post-SARDs (pregnancy following SARDs diagnosis) and pre-SARDs (pregnancy preceding SARDs diagnosis). Logistic, Cox and Poisson regression models evaluated the effects of SARDs on perinatal outcomes (small for gestational age [SGA] , congenital anomalies [CA], preterm delivery, major infection in baby) and maternal outcomes (major infections). All models were adjusted for maternal prescription medications, comorbidities, prior pregnancy outcomes, and BMI. RESULTS: Of 405,538 total pregnancies, 1400 had SARDs. 1011 pregnancies were post-SARDs, and 389 were pre-SARDs. Odds ratios (OR) for the association of SARD's with infants born SGA were increased for post-and pre-SARDs groups compared to nonSARDs pregnancies. The ORs for the association of SARDs with CA were increased only in the post-SARD's group. Hazard ratios (HR) for the effect of post-and pre-SARDs on preterm delivery were increased. Count ratios (CR) for the association of SARDs with a serious newborn infection were increased only in the pre-SARDs group. No increased risk seen for serious maternal infections. CONCLUSION: Increased risk of SGA, CA and preterm delivery was found in patients with SARD's. The risk of SGA, preterm delivery and newborn infections was increased prior to a SARD diagnosis. No association was seen between SARDs and maternal infections. 
The available inflammatory bowel disease (IBD) literature in pregnancy points to an increased risk of preterm birth (PTB), small for gestational age (SGA), and low birth weight, however there is little data regarding the effects of disease severity and use of biologics in pregnancy and postpartum. Our objective was to evaluate maternal, neonatal, and infectious outcomes categorized by disease severity and effect of immunomodulators in pregnancies affected by IBD. STUDY DESIGN: This was a retrospective cohort study of patients with IBD who were pregnant and delivered at a single tertiary care institution from 2012 to 2017. Controls were randomly selected from a set of pregnant patients without IBD during the same time frame. Rates of SGA and PTB were compared between cases and controls using logistic regression controlling for maternal age, BMI, history of PTB and race. Within cases, the incidence of maternal and neonatal composite outcomes were compared between groups defined by disease severity, flares in pregnancy, use of biologics, and use of infliximab postpartum using Chi-square and Fisher's exact tests. RESULTS: There were 219 patients included for analysis (101 with IBD and 118 without). Patients with IBD were more likely to be older (p¼0.0004), had a lower BMI (p¼0.0002), and were more likely to be Caucasian (p<0.0001) ( Table 1 ). The rate of PTB was significantly higher in cases (10.5%) compared to controls (1.7%), p¼0.01. This remained statistically significant in adjusted analysis (p¼0.03). SGA rates were comparable between cases (5.4%) and controls (5.9%), p¼0.86. Moderate-severe/severe disease was associated with an increased risk of maternal adverse outcome as compared to mild-moderate disease (88.2% versus 52.8%, p¼0.007). In addition, having a flare in pregnancy was associated with increased maternal adverse outcomes (90% versus 55.7%, p¼0.04). There was a trend towards significance for increased composite maternal adverse outcomes in patients using biologics (71.4% versus 50.9%, p¼0.06, Table 2 ). The use of infliximab postpartum was not Poster Session III 
